Everence Capital Management Inc Xencor Inc Transaction History

Everence Capital Management Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 07, 2022	BUY	$24.62 - $32.44 $206,808 - $272,496	8,400 New	8,400 $218,000
Q2 2022 Jul 26, 2022	SELL	$19.74 - $29.01 $212,007 - $311,567	-10,740 Closed	0 $0
Q1 2022 Apr 11, 2022	BUY	$26.68 - $41.63 $99,249 - $154,863	3,720 Added 52.99%	10,740 $287,000
Q4 2021 Jan 28, 2022	BUY	$33.67 - $43.44 $236,363 - $304,948	7,020 New	7,020 $282,000
Q3 2020 Oct 20, 2020	SELL	$30.09 - $43.02 $259,977 - $371,692	-8,640 Closed	0 $0
Q3 2019 Oct 09, 2019	BUY	$33.73 - $46.27 $291,427 - $399,772	8,640 New	8,640 $291,000

215

71.5M

2.5K

7.9K

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.44B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

Get notified when there are updates to the investment portfolio of Everence Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Everence Capital Management Inc with notifications on news.